<DOC>
	<DOC>NCT01592292</DOC>
	<brief_summary>This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF alpha therapy. Participants have commenced MabThera or an alternative anti-TNF alpha treatment as a second biological therapy. Data will be collected for 12 months.</brief_summary>
	<brief_title>An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult participants, &gt;/=20 years of age Participants with rheumatoid arthritis, who have not responded or have been intolerant to a single antiTNF alpha therapy and who have initiated MabThera or an alternative antiTNF alpha therapy Participants whose first antiTNF alpha treatment was, or second biological therapy is given as part of a clinical trial studying rheumatoid arthritis Participants who have not signed the informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>